BR112016018758B1 - Derivado da quitosana, composição cosmética, método de síntese e uso do referido derivado - Google Patents

Derivado da quitosana, composição cosmética, método de síntese e uso do referido derivado Download PDF

Info

Publication number
BR112016018758B1
BR112016018758B1 BR112016018758-0A BR112016018758A BR112016018758B1 BR 112016018758 B1 BR112016018758 B1 BR 112016018758B1 BR 112016018758 A BR112016018758 A BR 112016018758A BR 112016018758 B1 BR112016018758 B1 BR 112016018758B1
Authority
BR
Brazil
Prior art keywords
chitosan
glutathione
biopolymer
derivative
fmoc
Prior art date
Application number
BR112016018758-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016018758A2 (cg-RX-API-DMAC7.html
Inventor
Wojciech Bal
Izabela ZAWISZA
Tomasz FRACZYK
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL407258A external-priority patent/PL235482B1/pl
Priority claimed from PL407257A external-priority patent/PL234156B1/pl
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Publication of BR112016018758A2 publication Critical patent/BR112016018758A2/pt
Publication of BR112016018758B1 publication Critical patent/BR112016018758B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D105/00—Coating compositions based on polysaccharides or on their derivatives, not provided for in groups C09D101/00 or C09D103/00
    • C09D105/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B23/00—Obtaining nickel or cobalt
    • C22B23/04—Obtaining nickel or cobalt by wet processes
    • C22B23/0453—Treatment or purification of solutions, e.g. obtained by leaching
    • C22B23/0461—Treatment or purification of solutions, e.g. obtained by leaching by chemical methods
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B3/00—Extraction of metal compounds from ores or concentrates by wet processes
    • C22B3/20—Treatment or purification of solutions, e.g. obtained by leaching
    • C22B3/44—Treatment or purification of solutions, e.g. obtained by leaching by chemical processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/51—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Mechanical Engineering (AREA)
  • Metallurgy (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Environmental & Geological Engineering (AREA)
  • Birds (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Geology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
BR112016018758-0A 2014-02-19 2015-02-19 Derivado da quitosana, composição cosmética, método de síntese e uso do referido derivado BR112016018758B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PLP.407257 2014-02-19
PL407258A PL235482B1 (pl) 2014-02-19 2014-02-19 Sposób syntezy pochodnej chitozanu, pochodna chitozanu otrzymana tym sposobem, kompozycja kosmetyczna zawierająca pochodną chitozanu i zastosowanie pochodnej chitozanu
PL407257A PL234156B1 (pl) 2014-02-19 2014-02-19 Pochodna polioligosacharydu, chitation i kompozycja farmaceutyczna zawierająca chitation do zastosowania do zapobiegania alergii wywołanej metalami ciężkimi
PLP.407258 2014-02-19
PCT/PL2015/000023 WO2015126269A1 (en) 2014-02-19 2015-02-19 Method for synthesis of a biopolymer derivative, a biopolymer derivative and its use

Publications (2)

Publication Number Publication Date
BR112016018758A2 BR112016018758A2 (cg-RX-API-DMAC7.html) 2017-08-08
BR112016018758B1 true BR112016018758B1 (pt) 2022-04-12

Family

ID=52823760

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018758-0A BR112016018758B1 (pt) 2014-02-19 2015-02-19 Derivado da quitosana, composição cosmética, método de síntese e uso do referido derivado

Country Status (15)

Country Link
US (1) US20170056508A1 (cg-RX-API-DMAC7.html)
EP (1) EP3107941B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017513962A (cg-RX-API-DMAC7.html)
KR (1) KR20160122828A (cg-RX-API-DMAC7.html)
CN (1) CN106132978A (cg-RX-API-DMAC7.html)
AU (1) AU2015219586A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016018758B1 (cg-RX-API-DMAC7.html)
CA (1) CA2938964A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016002063A1 (cg-RX-API-DMAC7.html)
DK (1) DK3107941T3 (cg-RX-API-DMAC7.html)
EA (1) EA201691655A1 (cg-RX-API-DMAC7.html)
IL (1) IL247393A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016010696A (cg-RX-API-DMAC7.html)
SG (2) SG10201806997QA (cg-RX-API-DMAC7.html)
WO (1) WO2015126269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109569240B (zh) * 2018-12-14 2021-08-13 山东汇之蓝环保科技有限公司 高效脱硝离子液及其使用方法
CN109847572A (zh) * 2018-12-24 2019-06-07 深圳市寰保化工科技有限公司 一种微生物气泡液及其制备方法和应用
JP7587928B2 (ja) * 2020-05-15 2024-11-21 株式会社 資生堂 金属アレルギー原因物質ブロック剤
CN113521110B (zh) * 2021-07-12 2023-04-07 深圳零一生命科技有限责任公司 一种缓释抗逆性益生菌晶球及其制备方法
CN113842464B (zh) * 2021-09-24 2023-07-04 江苏贝美医疗科技有限公司 一种类风湿因子吸附材料及其制备方法与应用
AR130056A1 (es) * 2022-08-02 2024-10-30 Kannar Earth Science Ltd Composiciones y métodos para controlar patógenos de plantas que incluyen nematodos
CN116036358B (zh) * 2022-12-29 2026-02-06 南京大学 一种三维打印抗菌水凝胶材料及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009636A1 (en) 1990-11-30 1992-06-11 Baker Cummins Dermatologicals, Inc. Skin protective compositions and method of inhibiting skin irritation
CA2126132A1 (en) 1994-06-17 1995-12-18 Witold Neugebauer Peptide synthesis on chitosan
JP4008977B2 (ja) * 1997-01-27 2007-11-14 株式会社キレスト技研 キトサン誘導体及びその製法並びに金属イオン吸着剤
US20070299034A1 (en) * 2002-02-12 2007-12-27 Marie-France Versali Cell wall derivatives, their preparation process, and use thereof
DE10338110A1 (de) 2003-08-15 2005-03-10 Biomet Deutschland Gmbh Mit Chitosan beschichteter metallischer Gegenstand sowie Verfahren zu dessen Herstellung
RU2357738C2 (ru) 2007-07-09 2009-06-10 Государственное образовательное учреждение высшего профессионального образования "КРАСНОЯРСКАЯ ГОСУДАРСТВЕННАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ профилактики платиноза кожи
CN101759812A (zh) * 2009-12-28 2010-06-30 中国药科大学 一种新型仿穿膜肽结构的壳聚糖衍生物
CN102133433B (zh) * 2011-03-09 2013-12-18 中国人民解放军军事医学科学院基础医学研究所 一种可注射性心肌组织工程产品及其制备方法
CA2869821C (en) * 2011-06-13 2018-06-19 Rival, Societe En Commandite N,n,n-trialkylaminopolymers, methods of their preparation and uses thereof
PL233402B1 (pl) * 2012-08-03 2019-10-31 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Sposób oczyszczania ścieków o wysokiej zawartości metali, zwłaszcza srebra i miedzi
CN103266153B (zh) * 2013-06-17 2014-12-31 江西科技师范大学 一种改性壳聚糖的生产方法
CN104012839B (zh) * 2014-05-19 2016-04-06 中国人民解放军军事医学科学院基础医学研究所 保健品制备用壳聚糖-多肽复合物及其制备方法
CN104387503A (zh) * 2014-12-11 2015-03-04 湖南科技大学 壳聚糖-还原型谷胱甘肽聚合物的制备方法及其应用

Also Published As

Publication number Publication date
US20170056508A1 (en) 2017-03-02
KR20160122828A (ko) 2016-10-24
MX2016010696A (es) 2017-04-27
SG10201806997QA (en) 2018-09-27
EA201691655A1 (ru) 2017-01-30
CN106132978A (zh) 2016-11-16
AU2015219586A1 (en) 2016-08-18
WO2015126269A4 (en) 2015-10-01
CA2938964A1 (en) 2015-08-27
WO2015126269A1 (en) 2015-08-27
JP2017513962A (ja) 2017-06-01
EP3107941B1 (en) 2025-07-16
IL247393A0 (en) 2016-11-30
EP3107941A1 (en) 2016-12-28
SG11201606662QA (en) 2016-09-29
DK3107941T3 (da) 2025-10-20
CL2016002063A1 (es) 2017-05-26
BR112016018758A2 (cg-RX-API-DMAC7.html) 2017-08-08

Similar Documents

Publication Publication Date Title
Neufeld et al. Metal− Organic Framework/Chitosan Hybrid Materials Promote Nitric Oxide Release from S‑Nitrosoglutathione in Aqueous Solution
Gavel et al. Evaluation of a peptide-based coassembled nanofibrous and thixotropic hydrogel for dermal wound healing
Chang et al. Amphiphilic hydrogels for biomedical applications
EP3107941B1 (en) Method for synthesis of a biopolymer derivative, a biopolymer derivative and its use
Baral et al. A peptide-based mechano-sensitive, proteolytically stable hydrogel with remarkable antibacterial properties
Seferji et al. Green synthesis of silver-peptide nanoparticles generated by the photoionization process for anti-biofilm application
Jana et al. Gelatin-carboxymethyl tamarind gum biocomposites: in vitro characterization & anti-inflammatory pharmacodynamics
Lahmann Architectures of multivalent glycomimetics for probing carbohydrate–lectin interactions
Liu et al. Probing the Reversible Fe3+–DOPA-Mediated Bridging Interaction in Mussel Foot Protein‑1
Cherkupally et al. Solid-phase peptide synthesis (SPPS), C-terminal vs. side-chain anchoring: a reality or a myth
CN101759812A (zh) 一种新型仿穿膜肽结构的壳聚糖衍生物
CN107163159A (zh) 一种含卤素的壳聚糖季铵盐及其制备方法和应用
Torrens et al. Computational study of nanosized drug delivery from cyclodextrins, crown ethers and hyaluronan in pharmaceutical formulations
US10968286B2 (en) Site-selective modification of polysaccharides and applications thereof
RS62659B1 (sr) Postupak za proizvodnju konjugata hijaluronidaze sa derivatima polietilenpiperazina i primena proizvedenog konjugata
ES2386437T3 (es) Procedimiento de preparación de complejos moleculares
JP2007191643A (ja) 生体への定着性が付与されたポリアミノ酸誘導体
EP3392263A1 (en) Polypeptide compound, preparation method therefor and use thereof
CN110452315A (zh) 一种含硫脲盐的羧甲基壳聚糖衍生物及其制备方法和应用
EP3193952B1 (en) Composition containing glycosaminoglycans and proteins
PL234156B1 (pl) Pochodna polioligosacharydu, chitation i kompozycja farmaceutyczna zawierająca chitation do zastosowania do zapobiegania alergii wywołanej metalami ciężkimi
PL235482B1 (pl) Sposób syntezy pochodnej chitozanu, pochodna chitozanu otrzymana tym sposobem, kompozycja kosmetyczna zawierająca pochodną chitozanu i zastosowanie pochodnej chitozanu
CN114521199A (zh) 新型交联海藻酸结构体
Drozd et al. Effect of nanocrystalline particles of chitin on blood components in humans and experimental animals
JPH04506083A (ja) 連続した３個の基を有し、中央のものがα―アミノ酸性である化合物、およびその治療薬への適用

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/02/2015, OBSERVADAS AS CONDICOES LEGAIS.